Figure 3
From: Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
MOC31PE-induced anti-MOC31PE antibody generation was suppressed by CsA. The results from serum taken pre-treatment and at days 14, 28 and 42 post treatment are summarised, and the bars show percentage of patients with anti-MOC31PE antibodies. Black bar, MOC31PE alone. Grey bar, MOC31PE+CsA i.v. Each individual serum sample was analysed in triplicates, and at least two independent experiments were run. The Chi-square statistical analysis at both day 28 and day 42 showed significance, P<0.05, but not on day 14.
